ANZ 1103 (SOLACE) - Patients with metastatic BRCA-associated breast cancer, triple negative breast cancer or serous ovarian cancer receiving Olaparib (a PARP inhibitor) in combination with metronomic cyclophosphamide in a Phase I study to determine the maximum tolerated dose of this treatment combination

Trial Profile

ANZ 1103 (SOLACE) - Patients with metastatic BRCA-associated breast cancer, triple negative breast cancer or serous ovarian cancer receiving Olaparib (a PARP inhibitor) in combination with metronomic cyclophosphamide in a Phase I study to determine the maximum tolerated dose of this treatment combination

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Olaparib (Primary) ; Cyclophosphamide
  • Indications Advanced breast cancer; Fallopian tube cancer; Male breast cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Acronyms SOLACE
  • Most Recent Events

    • 06 Jun 2017 Results assessing safety and activity of olaparib in combination with oral cyclophosphamide in patients with metastatic triple negative breast cancer and recurrent high grade serous ovarian cancer, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 09 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 09 Sep 2016 Planned number of patients changed from 40 to 32.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top